Clinical trials · Virginia
Interstitial Lung Disease clinical trials in Virginia
We’re tracking 17 recruiting interstitial lung disease studies with a site in Virginia — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Virginia
- NCT07179380RecruitingPhase 3
A study of an inhaled drug for lung disease with high blood pressure
This trial tests an inhaled medicine (TPIP) for people with both lung scarring (interstitial lung disease) and high blood pressure in the lungs (pulmonary hypertension). It aims to see if the drug helps improve exercise ability and symptoms.
Richmond, VirginiaAges 18 years+ - NCT01915511Recruiting
Long-term registry for new or worsening lung scarring
This study collects health information over time from people with newly diagnosed idiopathic pulmonary fibrosis (IPF) or other lung scarring diseases that are getting worse. It’s meant to better understand disease patterns and outcomes, which may help doctors plan future care.
Charlottesville, VirginiaAges 21 years+ - NCT07201922RecruitingPhase 3
Can a new pill help slow lung changes in people with family risk?
This trial tests a new drug called nerandomilast to see if it can slow down early lung changes in people who have a close family member with a type of lung scarring called pulmonary fibrosis. You may join if you are 40 or older, have a parent, sibling, or child with this condition, and have early signs of lung changes on a CT scan.
Richmond, VirginiaAges 40 years+ - NCT04905693Enrolling by invitationPhase 3
Extension inhaled treprostinil study for fibrotic lung disease
This is an add-on (extension) study testing whether continuing inhaled treprostinil can help people with fibrotic lung disease who took part in earlier related studies. It mainly continues treatment and follow-up for eligible participants.
Charlottesville, VirginiaAges 40 years+ - NCT05892614RecruitingPhase 2
Efzofitimod for early systemic sclerosis lung scarring
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
Richmond, VirginiaAges 18 years+ - NCT06388421Recruiting
PH-ILD patient registry: tracking real-world outcomes
This study tracks people with both lung scarring and high blood pressure in the lungs (Group 3 PH-ILD) to better understand the disease and how treatments like Tyvaso work in real life. It may help you and your doctor make more informed decisions about your care.
Falls Church, VirginiaAges 18 years+ - NCT04930289Enrolling by invitation
Lung transplant registry for better donor lung preservation
This study builds a worldwide database to track and improve how donor lungs are preserved before transplant. Your information may help doctors choose and manage donor lungs more effectively.
Charlottesville, VirginiaAges Any age - NCT04896138Enrolling by invitation
Natural history study for lung scarring patients
This study follows people who are being seen for lung scarring (also called ILD) and compares them with family members without lung scarring. It helps researchers better understand how this condition changes over time and what to look for in the future.
Charlottesville, VirginiaAges 18 years+ - NCT06855329Recruiting
Studying progressive lung scarring (non-IPF)
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
Charlottesville, VirginiaAges 18–80 - NCT05943535RecruitingPhase 3
Breathing treprostinil to slow progressive lung scarring
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
Charlottesville, VirginiaAges 18 years+ - NCT07407933RecruitingPhase 1/Phase 2
YL201 with other cancer drugs for advanced solid tumors
This trial tests a new drug, YL201, combined with other cancer treatments for people with a certain type of advanced lung cancer (extensive-stage small cell lung cancer). It may help shrink tumors or slow their growth.
Fairfax, VirginiaAges 18 years+ - NCT07051707Recruiting
Study of a new lung treatment for people with COPD
This trial tests a device called dNerva that targets nerves in the lungs to help people with COPD breathe easier. It is designed for those who have moderate to severe COPD and are not currently smoking.
Richmond, VirginiaAges 40–80 - NCT06772623RecruitingPhase 1/Phase 2
Study of telisotuzumab adizutecan plus immunotherapy for advanced lung cancer
This trial tests a new combination treatment for people with advanced non-squamous non-small cell lung cancer who haven't received prior therapy for advanced disease and don't have specific gene changes. The treatment includes an antibody-drug conjugate (telisotuzumab adizutecan) plus an immunotherapy drug (PD-1 checkpoint inhibitor) to see if it helps shrink tumors and improve outcomes.
Leesburg, VirginiaAges 18 years+ - NCT07365241RecruitingPhase 3
Study of ABBV-706 vs standard care for advanced small cell lung cancer
This trial tests a new drug called ABBV-706 against standard treatments (topotecan, lurbinectedin, or amrubicin) for people with small cell lung cancer that has come back or stopped responding to previous therapies. The goal is to see if ABBV-706 works better at controlling the cancer.
Blacksburg, VirginiaAges 18 years+ - NCT07155174RecruitingPhase 2
Testing new drug combo for first-line extensive small cell lung cancer
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
Fairfax, VirginiaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Fairfax, VirginiaAges 18 years+ - NCT07005102RecruitingPhase 2/Phase 3
Telisotuzumab adizutecan and osimertinib for EGFR-positive lung cancer
This trial tests a new drug combination (telisotuzumab adizutecan plus osimertinib) as a first treatment for adults with a specific type of advanced lung cancer that has an EGFR mutation. The goal is to see if the combination is safe and works better than standard care.
Fairfax, VirginiaAges 18 years+
Interstitial Lung Disease trials by city in Virginia
Where these studies are running in Virginia
Institutions with a site for the recruiting interstitial lung disease studies listed above.
- Inova Fairfax Medical Campus · 3 studies
- Pulmonary Associates of Richmond, Inc. · 3 studies
- University of Virginia · 3 studies
- University of Virginia Health System · 2 studies
- Virginia Cancer Specialists · 2 studies
- Virginia Commonwealth University · 2 studies
- aTyr Investigative Site
- Christopher King, MD
What taking part in a interstitial lung disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Interstitial Lung Disease trials in other states
Common questions
- Are there interstitial lung disease clinical trials in Virginia?
- Yes. We're currently tracking 17 recruiting interstitial lung disease studies with a site in Virginia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a interstitial lung disease study in Virginia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Virginia to take part?
- Not necessarily. These studies have a site in Virginia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a interstitial lung disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New interstitial lung disease studies open in Virginia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.